Respiration
Original Paper
Role of Bromhexine in Exacerbations of BronchiectasisDouble-Blind Randomized Multicenter Study versus Placebo aDepartment of Respiratory Diseases, University of Parma, Italy; bDepartment of Phthisiology and Respiratory Diseases, University of Ferrara, Italy; cDepartment of Phthisiology and Respiratory Diseases, University of Catanzaro, Italy; dDepartment of Respiratory Pathophysiology, University of Perugia, Italy, and eMedical Department, Boehringer Ingelheim Italia, Florence, Italy
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Received: July 26, 1989
Accepted: June 05, 1991
Published online: January 20, 2009
Issue release date: 1991
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0
ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)
For additional information: https://www.karger.com/RES
Abstract
The effectiveness of bromhexine in the treatment of patients with bronchiectasis, in a stage of clinical exacerbation, was assessed in a double-blind, placebo-controlled trial involving 88 in-patients. Bronchiectasis was diagnosed by bronchography and/or CT scan. Bromhexine or matched placebo was administered as 30-mg capsules three times daily per os. Ceftazidine, 1 g i.m., was given to all patients once a day for the first week only. Bromhexine seemed to improve the clinical picture, with significantly positive trends for expectoration, quantity of sputum and auscultatory findings. It also increased the FEV1 and was well-tolerated. Both patients and investigators judged it efficacious
© 1991 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Received: July 26, 1989
Accepted: June 05, 1991
Published online: January 20, 2009
Issue release date: 1991
Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0
ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)
For additional information: https://www.karger.com/RES
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission